ER+ BREAST CANCER

This study tests whether the drug elacestrant can clear traces of cancer DNA found in the blood of people with hormone receptor-positive breast cancer who are at risk of late recurrence. About 50 adults whose blood tests positive for tumor DNA but show no visible spread will take…

This study looks at whether giving hormone therapy before breast-conserving surgery helps reduce leftover cancer cells at the edges of removed tissue. It involves 176 postmenopausal women with stage 2-3 ER+/HER2- invasive lobular carcinoma. The goal is to see if this approach lea…

This study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This study is for people with a common type of advanced breast cancer (ER-positive/HER2-negative) that cannot be removed by surgery or has spread. It tests a new drug called FWD1802 combined with other treatments to find the safest dose and see if it shrinks tumors. About 196 par…

This study tests whether giving radiation again after a second lumpectomy is safe for women with a common type of breast cancer (ER+HER2-). About 114 women who had radiation before and whose cancer came back at least 18 months later will receive targeted radiation over 3 weeks. T…

This study is for 500 adults with non-metastatic breast cancer who are about to start treatment like chemotherapy or targeted therapy before surgery. Researchers will collect tumor tissue, blood, and sometimes stool samples and MRI scans during treatment. The goal is to learn why…

This study tests whether a decision aid and training for surgeons can help women aged 70 and older with low-risk stage I breast cancer make better treatment choices. About 402 participants will be split into two groups: one where surgeons get shared decision-making training and p…

This pilot study tests whether a special PET scan (FES-PET/CT) can help doctors find the best dose of tamoxifen for people with metastatic breast cancer that has an ESR1 mutation. These mutations can make standard tamoxifen doses less effective. The study will enroll 12 participa…